Home > Institute Collections > W500 > Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. > print

001     305768
005     20251118120039.0
024 7 _ |a 10.1038/s41598-021-87102-4
|2 doi
024 7 _ |a pmid:33828163
|2 pmid
024 7 _ |a pmc:PMC8027413
|2 pmc
037 _ _ |a DKFZ-2025-02385
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Ottolenghi, Aner
|b 0
245 _ _ |a Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.
260 _ _ |a [London]
|c 2021
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763463621_1939189
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKFZ-MOST-Ca172# / #DKFZ-MOST-Ca199#
520 _ _ |a IL-2 is the master-regulator cytokine for T cell dependent responses and is crucial for proliferation and survival of T cells. However, IL-2-based treatments remained marginal, in part due to short half-life. Thus, we aimed to extend IL-2 half-life by flanking the IL-2 core with sequences derived from the extensively glycosylated hinge region of the NCR2 receptor. We termed this modified IL-2: 'S2A'. Importantly, S2A blood half-life was extended 14-fold compared to the clinical grade IL-2, Proleukin. Low doses inoculation of S2A significantly enhanced induction of Tregs (CD4+ Regulatory T cells) in vivo, as compared to Proleukin, while both S2A and Proleukin induced low levels of CD8+ T cells. In a B16 metastatic melanoma model, S2A treatment was unable to reduce the metastatic capacity of B16 melanoma, while enhancing induction and recruitment of Tregs, compared to Proleukin. Conversely, in two autoimmune models, rheumatoid arthritis and DSS-induced colitis, S2A treatment significantly reduced the progression of disease compared to Proleukin. Our results suggest new avenues for generating long-acting IL-2 for long-standing treatment and a new technique for manipulating short-life proteins for clinical and research uses.
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Delayed-Action Preparations
|2 NLM Chemicals
650 _ 7 |a Interleukin-2
|2 NLM Chemicals
650 _ 7 |a Natural Cytotoxicity Triggering Receptor 2
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Arthritis, Rheumatoid: prevention & control
|2 MeSH
650 _ 2 |a Autoimmunity: drug effects
|2 MeSH
650 _ 2 |a Delayed-Action Preparations
|2 MeSH
650 _ 2 |a Drug Evaluation, Preclinical
|2 MeSH
650 _ 2 |a Glycosylation
|2 MeSH
650 _ 2 |a Half-Life
|2 MeSH
650 _ 2 |a Interleukin-2: administration & dosage
|2 MeSH
650 _ 2 |a Interleukin-2: analogs & derivatives
|2 MeSH
650 _ 2 |a Interleukin-2: pharmacokinetics
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Natural Cytotoxicity Triggering Receptor 2: chemistry
|2 MeSH
650 _ 2 |a T-Lymphocytes, Regulatory: drug effects
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
700 1 _ |a Bolel, Priyanka
|b 1
700 1 _ |a Sarkar, Rhitajit
|b 2
700 1 _ |a Greenshpan, Yariv
|b 3
700 1 _ |a Iraqi, Muhammed
|b 4
700 1 _ |a Ghosh, Susmita
|b 5
700 1 _ |a Bhattacharya, Baisali
|b 6
700 1 _ |a Taylor, Zoe V
|b 7
700 1 _ |a Kundu, Kiran
|b 8
700 1 _ |a Radinsky, Olga
|b 9
700 1 _ |a Gazit, Roi
|b 10
700 1 _ |a Stepensky, David
|b 11
700 1 _ |a Apte, Ron N
|b 12
700 1 _ |a Voronov, Elena
|b 13
700 1 _ |a Porgador, Angel
|b 14
773 _ _ |a 10.1038/s41598-021-87102-4
|g Vol. 11, no. 1, p. 7676
|0 PERI:(DE-600)2615211-3
|n 1
|p 7676
|t Scientific reports
|v 11
|y 2021
|x 2045-2322
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-29T15:28:26Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
980 _ _ |a journal
980 _ _ |a I:(DE-He78)W500-20160331
980 _ _ |a I:(DE-He78)W510-20160331
980 1 _ |a EXTERN4COORD

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21